Clearpoint Neuro Inc (CLPT)vsNovartis AG ADR (NVS)
CLPT
Clearpoint Neuro Inc
$14.14
-2.68%
HEALTHCARE · Cap: $450.74M
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 139490% more annual revenue ($56.69B vs $40.61M). NVS leads profitability with a 22.5% profit margin vs -71.6%. CLPT appears more attractively valued with a PEG of 0.61. NVS earns a higher WallStSmart Score of 51/100 (C-).
CLPT
Hold37
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.2%
Fair Value
$14.88
Current Price
$14.14
$0.74 discount
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$158.83
$66.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.9% year-over-year
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 22.4x book value
ROE of -154.3% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 42.9% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : CLPT
The primary concerns for CLPT are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 3.37 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CLPT profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
CLPT carries more volatility with a beta of 1.24 — expect wider price swings.
CLPT is growing revenue faster at 42.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?